Chime and Polpharma Biologics Collaborate on Global Biosimilar Development

Chime Biologics, a prominent global contract development and manufacturing organization (CDMO), has announced a strategic partnership with Polpharma Biologics to advance the development and production of a biosimilar product for the international market. This collaboration highlights Chime Biologics' dedication to delivering high-quality and cost-effective biologics, further bolstering its presence in the European biosimilar sector.

Through this agreement, Chime Biologics will offer comprehensive support to Polpharma Biologics for the development of a biosimilar, covering stages from investigational new drug (IND) to commercial production. This endeavor aims to accelerate the time-to-market for biosimilar therapies and ensure a rapid entry into the global market.

Polpharma Biologics, recognized as a significant player in the biosimilar industry and the largest biotechnology company in Poland, has a strong pipeline that includes both early-stage and late-stage biosimilars. It currently manufactures two biosimilars that have been approved by both the FDA and EMA. This extensive experience positions the company well to meet the increasing global demand for biosimilars.

Chime Biologics offers a comprehensive range of services from cell line development to commercial supply, incorporating state-of-the-art process and analytical development capabilities. This full-spectrum service ensures that clients can swiftly transition from development to market-ready products, thereby meeting the growing needs of the biosimilar market.

Dr. Jimmy Wei, President of Chime Biologics, expressed enthusiasm about the collaboration, stating that this partnership enables the company to provide integrated solutions that accelerate biosimilar development and reduce the time required to reach the market. He emphasized that this alliance is part of Chime Biologics' strategy to deliver high-quality and affordable biologics to patients worldwide.

Konstantin Matentzoglu, a member of the Supervisory Board of Polpharma Biologics Group BV, echoed similar sentiments, highlighting that partnering with Chime Biologics is aligned with their strategic vision to bring cost-effective biosimilars developed in Europe to global markets quickly. The collaboration is expected to enhance Polpharma Biologics' capability to provide patients with faster access to biosimilar therapies, thereby strengthening its position as a leading developer in the global biosimilars market.

Polpharma Biologics, an international biotech company with operations across the European Union, focuses on developing and manufacturing biosimilar medicines. The company undertakes comprehensive programs starting from cell line development and advancing through technical, clinical, and commercial-scale production. It aims to prepare its products for future commercial partnerships with major global pharmaceutical organizations. Polpharma's facilities, including a cell line development center in the Netherlands and two development and manufacturing centers in Poland, contribute to its robust capabilities in biotechnology.

Chime Biologics, as a global CDMO, is dedicated to ensuring the success of its partners in delivering innovative biologics worldwide. The company offers a complete array of services from pre-clinical support and cell line development to clinical and commercial manufacturing. Their mission is to make advanced biomedicines affordable and accessible to patients globally, in alignment with their commitment to improving human health.